Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

4.12USD
4:00pm EDT
Change (% chg)

$-0.10 (-2.37%)
Prev Close
$4.22
Open
$4.23
Day's High
$4.23
Day's Low
$4.11
Volume
599,211
Avg. Vol
1,352,662
52-wk High
$7.15
52-wk Low
$2.62

SGYP.OQ

Chart for SGYP.OQ

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $941.55
Shares Outstanding(Mil.): 223.12
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 58.07 30.12
EPS (TTM): -1.28 -- --
ROI: -253.37 0.23 13.28
ROE: -- 6.18 14.44

BRIEF-Synergy Pharmaceuticals appoints Gary Gemignani as chief financial officer

* Synergy Pharmaceuticals appoints Gary G. Gemignani as chief financial officer

Apr 17 2017

BRIEF-Synergy Pharmaceuticals announces issuance of three new patents expected to extend Trulance patent protection until 2032

* Announces issuance of three new patents expected to extend Trulance (Plecanatide) patent protection until 2032

Apr 12 2017

BRIEF-Synergy Pharmaceuticals reports qtrly net loss per common share $0.31

* Synergy Pharmaceuticals reports fourth quarter and full year 2016 financial results and business update

Mar 01 2017

BRIEF-Synergy Pharmaceuticals provides update on phase 3 data results for Trulance

* Pivotal phase 3 data results for Trulance(Tm) (plecanatide) in the treatment of chronic idiopathic constipation (CIC) published in American Journal Of Gastroenterology

Feb 07 2017

Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)

Jan 24 2017

CORRECTED-UPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19)

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 24 2017

BRIEF-Synergy Pharma's Trulance receives FDA approval for treatment of adults with chronic idiopathic constipation

* Synergy Pharmaceuticals' Trulance(TM) (Plecanatide) receives U.S. FDA approval for the treatment of adults with chronic idiopathic constipation

Jan 19 2017

Synergy wins U.S. approval for constipation drug

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC). (http://bit.ly/2k5wNlA)

Jan 19 2017

BRIEF-FDA approves Trulance for chronic idiopathic constipation

* FDA- Trulance is manufactured by New York, New York-based Synergy Pharmaceuticals Inc Source text for Eikon: Further company coverage:

Jan 19 2017

Synergy Pharma's irritable bowel drug succeeds in key study

Synergy Pharmaceuticals Inc said its experimental once-daily tablet, plecanatide, met the main goal of a late-stage study on irritable bowel syndrome patients with constipation (IBS-C), according to an analysis of preliminary data.

Dec 09 2016

More From Around the Web

Earnings vs. Estimates